Oxford BioMedica Live Discussion

techno-foxx 21 Jun 2018

Cat- t setback for compitition BioPharma Dive Ziopharm shares tumble as clinical hold delays CAR-T The FDA put a halt to the company's Phase 1 trial before it even began, seeking more information on the company's manufacturing plans.

John_of_Groats 21 Jun 2018

OXB Us doing well at the moment loadsa, OXB has done well only if you bought at the right time (or sold at the right time). I bought my first shares in 2003 when the price was equivalent to around £10, so those shares have not earned anything for 15 years. The worst thing I did was to buy in early 2007 when the shares were around £25. The best was to buy in mid 2013 when the shares were about 80p. John

loadsadough 16 Jun 2018

OXB Us doing well at the moment Here is a stock to have a good look at OXB. So far it has done very well. Loadsadough

d_gaser 16 Jun 2018

Novartis Kymriha Juliet trial demontrates durability in adults Received an E Mail this morning from Novartis regarding Kymriah ,and it’s good news BE HAPPY DAVE Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL • Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable[1] • Patients had a 65% chance of being relapse-free one year after onset of response[1] • With eight months of additional follow-up, response rates remained consistent with previous reports and the safety profile was maintained with no emergence of new safety signals Basel, June 16, 2018 - Novartis today announced 14-month results from the pivotal JULIET clinical trial showing ongoing durable responses are achievable with Kymriah® (tisagenlecleucel) when administered to adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The overall response rate (ORR) was 52% (95% confidence interval [CI], 41% - 62%), among 93 evaluable patients who were followed for at least 3 months or discontinued earlier[1]. A complete response (CR) was achieved in 40% of patients and 12% achieved a partial response (PR). Of the patients in CR at month 3, 83% remained in CR at month 12, and the median duration of response was not reached, indicating sustainability of response. These data will be presented in an oral presentation at the 23rd Annual Congress of the European Hematology Association (EHA) (Abstract # S799; Saturday, June 16, 11:30AM CEST)[1]. “Advanced aggressive lymphoma patients who once faced a poor prognosis now have the possibility of sustained remission after a single course of therapy - a previously unimaginable and revolutionary breakthrough,” said the lead author of the updated JULIET analysis Peter Borchmann, MD, Department of Internal Medicine, University Hospital of Cologne, Germany. “With 14 months of data from JULIET, we are seeing that Kymriah may continue to redefine outcomes for patients with relapsed or refractory DLBCL.” In the JULIET study, the relapse-free probability at 12 months after a patient’s first response (n=48) was 65% (95% CI, 49%-78%). In fact, 54% (13/24) of patients who had achieved a PR converted to CR, including two patients between months 9 and 12. Median overall survival (OS) was not reached for patients in CR (95% CI, 17.9-NE). The OS rate at 12 months was 49% and median OS was 11.7 months among all infused patients (n=111) (95% CI, 6.6-NE). The median time from infusion to data cutoff was 14 months with a maximum time from infusion of 23 months. At the time of data cutoff, no patients in response following treatment with Kymriah proceeded to stem cell transplant[1]. “These results from JULIET continue to show Kymriah delivers strong efficacy with durable responses, and a predictable and consistent safety profile more than a year after infused in patients with advanced DLBCL,” said Samit Hirawat, MD, Head, Novartis Oncology Global Drug Development. “Novartis is committed to bringing this important and innovative treatment option to more patients around the world.” Within eight weeks of infusion with Kymriah, Grade 3/4 cytokine release syndrome (CRS), as defined by the Penn Grading Scale - a rigorous scale for grading CRS -, was reported in 22% of patients (14% grade 3; 8% grade 4). Fifteen percent of patients received tocilizumab for treatment of CRS, including only 3% of patients with Grade 2 CRS and 50% of patients with Grade 3 CRS. CRS is a known complication of CAR-T therapy that may occur when the engineered cells become activated in the patient’s body. CRS was managed globally using prior site education on implementation of the CRS treatment algorithm. No deaths due to cerebral edema were reported[1]. In this analysis, 12% of patients had grade 3/4 neurologic adverse events, which were managed with supportive care. Grade 3/4 cytopenias lasting more than 28 days, grade 3/4 infections and grade 3/4 febrile neutropenia occurred in 32%, 20% and 15% of patients, respectively[1]. For more info go to www.novartis.com/news/media-releases/novartis-juliet-trial-kymriah-demonstrates-more-one-year-durability-responses-adults-relapsed-or-refractory-dlbcl

d_gaser 14 Jun 2018

OXB broker hike to 1100p Oxford Biomedica’s long-awaited OXB-102 deal did not disappoint Jefferies, but analysts felt the share price was up with events. The broker hiked its target price on the biopharmaceutical company from 825p to 1,100p but noted that with an “insufficient near-term upside” left, it was time to lower the stock to ‘hold’ from its former ‘buy’ rating. Despite the downgrade, Jefferies said it remained confident that Oxford Biomedica’s Parkinson’s treatment was on a path to sustainable profitability and envisages an “escalating interest” in its proprietary Lenti platform, the long-awaited Phase I/II trial set to start by the end of the year. Jefferies felt Oxford Biomedica’s Axovant deal, which saw OXB-102 licensed to Axovant for $30m upfront, up to $812.5m in future milestones and 7%-10% royalties on sales, was “critical” to the firm as the terms “amply surpass” its prior $200m and 8%-11% assumptions. Jefferies said, “The recent deal with Axovant for AXO-Lenti-PD increases confidence OXB can successfully establish externally funded vehicles or secure out-licensing deals for the continued clinical development of its two remaining priority pipeline programmes, which we believe should raise awareness of these largely overlooked assets.”

techno-foxx 14 Jun 2018

Billion dollar deal its not just this near billion dollar deal, as the drug experts also predicted that Cart-T treatment will be a billion dollar treatment?

supeman1 14 Jun 2018

Long wait for profits I have been here for years. Imho I would be very very carefully and not jump in just now. Give it another month or two.

Chicken Lips 08 Jun 2018

Re: Holy Grail It is interesting that mortality rates are actually getting lower due to obesity and other lifestyle consequences juts at the same time we do seem to be nearing cures for what were considered incurable diseases.I think from an investor perspective we hope that OXB is the beneficiary of this long term investment into research and development. Seems to be being noticed and invested in at the moment. Sentiment and good news stories. I tell you miracle cures.

Rain-Stalker 08 Jun 2018

Re: Holy Grail Can you imagine the mothering law living that long!

Roger Baron 08 Jun 2018

Re: Holy Grail Living to 200! About 6 years ago I heard that a Prof at Durham Uni, who was accepted as being one of the top experts in the world on the ageing process, reckoned that the first person who would live to be 1,000 was already born. (I know he wasn't thinking about me ha ha)

Rain-Stalker 08 Jun 2018

Holy Grail Am I seeing this right? An article in the Times Re: a Miracle Cure by scientise extracting T cell growing her own cells put back and tumour completely gone in two weeks. Now, it may not be OXB however they have been working on stimulating patients own immune system since time began.I remember reading when trials were stopped and share price collapsed someone suggested they needed a patient so advanced they were no-hopers! Well, that's happened. Does this mean the dawn of humans living to 200-year-olds? The money this could mean a company like OXB is mind-blowing. Any views?

S17 06 Jun 2018

Still not back to where we were 10 years ago... ....but certainly excellent progress - just hope it can be sustained this time; [link]

techno foxx 06 Jun 2018

more on todays deal [link]

Chicken Lips 06 Jun 2018

Re: Great news, but don't get carried aw... I think these are both good posts. Thanks for the information.A great deal of todays hike must be on future earning potential and to just this deal but other and future deals now that the technology seems to be being realised.Dont underestimate sentiment. It can drive shares to giddy heights (as well as impossible to believe lows). The sentiment wind blows in the right direction currently, so investors start to see all positives rather than negatives so all upside today on the news?

doc-lee 06 Jun 2018

Re: Great news, but don't get carried away I share some of Pharmaspecialist's concern re management.Just look at NWBO (NorthWestBiotherapeutics) whose shares I have held for the last 6 years. The company has a world-beating product, DCVax-L, which was quite rightly plastered all over the papers and TV last week for the marked improvement in survival it confers on some patients with glioblastoma multiforme. Despite this its shares are still being shorted to perdition and the SP is languishing at about 30 cents having been up at $7-8 only a few years ago. The company is run by lawyers who have been so cack-handed in their public dealings that the shorters did not know whether to attack the company for its management's incompetence or its perceived dishonesty and dubious financial practices. Result, despite stellar results in its Phase 3 clinical trial its future survival is still in significant doubt.Look it up on ADVFN for a taste of what "amateur" owners of biopharmaceutical research companies are capable of doing.